No Data
Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial
ZHAOKE OPHTH-B (06622.HK): The first patient has been enrolled in the new round of Phase III clinical trials for Cyclosporin A eye gel.
On April 17, Glonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that the Phase III clinical trial of cyclosporine A eye gel (one of the company's candidate drugs) for the treatment of moderate to severe dry eye syndrome began enrolling the first patient on April 3, 2025. This Phase III clinical trial is a multicenter, randomized, double-blind, and placebo-controlled study assessing the efficacy and safety of cyclosporine A eye gel in patients with moderate to severe dry eye syndrome. The trial is led by Professor Liu Guoguo, Chief Physician at the Xiamen University Eye Research Institute, and will involve 25 centers with a total enrollment of 360 patients. It is scheduled to conclude in July 2024.
Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal
ZHAOKE OPHTH-B (06622.HK) has signed three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL PF, and six glaucoma medications in Thailand.
On April 16, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that the company has entered into three distribution and supply agreements with Interpharma for the commercialization in Thailand of (i) NVK002 (an innovative therapy to control the progression of myopia); (ii) BRIMOCHOL PF (an innovative drug for the treatment of presbyopia); and (iii) six generic drugs for glaucoma (Bimatoprost, Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol) (collectively referred to as "the products"). According to the terms of the agreements, ZHAOKE OPHTH-B will grant...
Express News | Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand
ZHAOKE OPHTH-B (06622.HK): Tenpoint has submitted a new drug application for BRIMOCHOLPF to the FDA, accelerating the global process for the treatment of presbyopia.
On April 11, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced the enrollment of the first patient in the Phase II clinical trial of BRIMOCHOLPF (one of the company's candidate drugs, indicated for presbyopia) on March 24, 2025. This Phase II clinical trial is a multicenter, randomized, double-blind, crossover, and placebo-controlled study. The main objective of the trial is to evaluate the efficacy and safety of BRIMOCHOLPF eye drops in Chinese patients with presbyopia. The trial is led by Professor Qu Jia from the Wenzhou Medical University Affiliated Eye Hospital and will involve 14 centers, and
